Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

Results Show Superior Decrease in Pain Scores Compared to Saline

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA(R) (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA (R) is superior to saline in decreasing pain at 26 weeks in patients with OA of the knee.(1) The study results were presented by Dr. Roy D. Altman in a poster at the Annual Meeting of the American Academy of Orthopedic Surgeons on February 23, 2009.

EUFLEXXA(R) is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of hyaluronic acid (HA) therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

About the Study

The multicenter, 26-week, randomized, double-blind trial compared EUFLEXXA(R) and intra-articular buffered saline (IA-SA) for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale (VAS). The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for 3 weeks with 9 follow-up visits over 26 weeks after the first injection.

The EUFLEXXA(R) group showed an advantage over saline in pain reduction, with a larger mean decrease from baseline in pain scores: -25.7 (28.9) mm versus -18.5(32.5) mm respectively, with a least squares means of -6.6 mm (P=0.002). At 26 weeks, 145 (58%) of EUFLEXXA(R) subjects reported a greater than or equal to 20-mm improvement in pain based on the VAS scoring, compared with 120 (46%) in the o
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/28/2015)... , August 28, 2015 ... seamlessly connects people, technologies and care protoc ols ... outcomes and the cost of healthcare delivery   ... its presence at  ESC Congress 2015 , where the company ... , EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology ...
(Date:8/27/2015)...  The Academy of Managed Care Pharmacy (AMCP) ... draft guidance and proposed rule that calls for ... a nonproprietary name with an FDA-designated suffix. For ... from the FDA on the naming issue and ... the agency to use the same nonproprietary names ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Vical Incorporated (Nasdaq:,VICL) announced today that results ... trials, using a plasmid DNA (pDNA) vaccine developed ... Vical, reinforced previously,reported Phase 1 conclusions that a ... well-tolerated, and was effective in inducing,T-cell immune responses ...
... Single, Higher, More Concentrated Dose of ... ... Inc.,(Nasdaq: NUVO ) today announced enrollment of the first patient ... trial evaluating lead product candidate,alfimeprase, for the treatment of central venous ...
Cached Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... PRINCETON, N.J., March 9 NJHA Corporate Services ... Morganville, N.J., to offer training and consulting services ... the healthcare environment. The deal comes on the ... Facilities Act, which directs healthcare facilities to establish ...
... Pa., March 9 Genaera Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in the ... the fiscal year ended December 31, 2008 contained an ... firm, KPMG LLP, which included a "going concern" explanatory ...
... action, which is expected to kick-start efforts to unlock ... Separating science from politics with his signature, President Barack ... research on Monday. , During a late morning press ... limits on such research that were first imposed by ...
... Name Youth as ,First Responders, , in the ... order to address the growing childhood obesity epidemic, ... supporting youth-led projects that focus on healthy lifestyles ... two national partners also published an educational guide ...
... against the disease, study finds , , MONDAY, March 9 (HealthDay ... that puts them at higher risk of breast cancer tend ... Several type of risk management strategies are available to women ... is known to elevate a woman,s risk of breast cancer. ...
... Medicare Advantage Special Needs Plans, Tips for Healthy ... A series of free seminars designed to help ... a healthy lifestyle and learn about Medicare Advantage ... will be offered during March at various locations ...
Cached Medicine News:Health News:NJHA, McNamara and Associates Inc. Team Up to Provide Strategies for Controlling Workplace Violence 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Obama Lifts Ban on Stem Cell Research 2Health News:Obama Lifts Ban on Stem Cell Research 3Health News:Obama Lifts Ban on Stem Cell Research 4Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 2Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 3Health News:Women With Breast Cancer Gene Favor Preventive Mastectomy 2Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
... genuine BOOKWALTER™ Retractor System represents the ... design available. Its wide array of ... with a versatile system for multi-directional ... BOOKWALTER™ Kits are available for specific ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... Another breakthrough in real-time PCR analysis ... mutation analysis. ,The LightCycler 480 System ... and will meet the needs of ... in genomics research including array validation, ...
Medicine Products: